Clinical trial · Interventional
DOTATATE PET for Meningioma Radiation Planning
Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DOTATATE-PET scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DOTATATE-PET scan
- interventionNames
- Diagnostic Test: DOTATATE-PET scan
Primary outcomes (1)
- measure
- Target radiation volume
- timeFrame
- 2 years
- description
- The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan
Secondary outcomes (7)
- measure
- Local control
- timeFrame
- 2 years
- measure
- Progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old * Able and willing to comply with the study procedures * Intact meningioma requiring definitive radiation * Post-operative meningioma requiring adjuvant radiation * No prior radiation therapy or medical therapy directed at the tumour Exclusion Criteria: * Breastfeeding or pregnancy * Claustrophobia or inability to lie still in a supine position * Unwillingness or inability to provide informed consent
References
Publications (0)
Data not yet available